Company intelligence / Profile preview

Alwatec

Ownership: Private
Development stage: Other

Overview

Alvotech has achieved rapid commercial success with multiple biosimilars launched globally. In 2024 its revenues surged over 400% year-over-year due to strong sales of AVT02 (adalimumab) and AVT04 (ustekinumab). The company continues to expand its pipeline with additional late-stage candidates targeting major biologics such as Eylea® and Keytruda®.

Therapeutic areas: PulmonologyOphthalmologyEndocrinologyOncologyImmunology
Modalities: BiologicMonoclonal antibodyRecombinant protein
Industry: Biotech

Partnerships

Teva Pharmaceuticals (US)STADA Arzneimittel AG (EU)Fuji Pharma Co., Ltd. (Japan)Advanz Pharma (Europe ex-Germany/France + UK + Switzerland + Canada + Australia/NZ)Cipla/Cipla Gulf/Cipla Med Pro/Africa/Australia/NZ/South Africa/Africa region partnersJAMP Pharma Corporation(Canada)Yangtze River Pharmaceutical Group(China)

Beyond the preview

Go deeper on Alwatec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alwatec.

Explore the full profile